Walleye Capital’s Cellebrite CLBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$108K Sell
7,400
-18,200
-71% -$241K ﹤0.01% 3860
2026
Q1
$353K Buy
25,600
+19,300
+306% +$291K ﹤0.01% 2938
2025
Q4
$114K Sell
6,300
-1,400
-18% -$25.1K ﹤0.01% 3818
2025
Q3
$143K Buy
7,700
+5,500
+250% +$86.4K ﹤0.01% 3523
2025
Q2
$35.2K Sell
2,200
-100
-4% -$1.78K ﹤0.01% 4129
2025
Q1
$44.7K Sell
2,300
-25,200
-92% -$530K ﹤0.01% 3884
2024
Q4
$606K Sell
27,500
-53,400
-66% -$1.03M ﹤0.01% 2840
2024
Q3
$1.36M Buy
+80,900
New +$1.2M ﹤0.01% 2326

Other funds holding CLBT

Walleye Capital's CLBT Position: Q2 2026 in Review

Walleye Capital opened a new position in Cellebrite (CLBT) in Q2 2026: 30 shares worth $438. The stake represents ﹤0.01% of the portfolio and ranks #4620 among its holdings. This is a return to the name: Walleye Capital previously reported a position in CLBT as recently as Q4 2025.

Walleye Capital first reported a position in CLBT in Q4 2023 and has held it in 10 quarters since. The position peaked at $20M in Q3 2024. 201 funds tracked by Wall St. Rank hold CLBT as of Q2 2026.

  • Walleye Capital held 30 shares of Cellebrite worth $438 as of Q2 2026.
  • Cellebrite was a new Walleye Capital position in Q2 2026.
  • Cellebrite made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #4620 holding.
  • Walleye Capital first reported a position in Cellebrite in Q4 2023 and has held it in 10 quarters since.
  • Walleye Capital's Cellebrite position peaked at $20M in Q3 2024.
  • 201 funds tracked by Wall St. Rank held Cellebrite as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.